Watch XENE. Know when insiders buy.
One email the day a filing lands. Free.
XENE
Xenon Pharmaceuticals Inc.
36.39
+0.44 +1.22%
USD · close Oct 22
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
54
WATCH · insiders 85, shorts 23
Insiders, 90 days
+$1.3M
net buying · 2 buys, 2 sells
Congress, 90 days
0 / 0
no disclosures naming it
Big money
1 / 15
tracked funds hold it
Calls on record
0
nobody we score has called it yet
MKT CAP $3.5BP/E —DIV YIELD —FCF YIELD -9.61%REV TTM —NET INCOME −$409.2MNET CASH $93M52W 33.49 – 70.96NEXT EARNINGS Nov 2SEC XBRL · TTM TO Invalid Date
Who holds it
| Fund | Type | Rank in portfolio | Value | Shares | As of |
|---|---|---|---|---|---|
| Duquesne Family Office (Stanley Druckenmiller) | Guru | #63 | $14.4M | 239K | 2026-06-30 |
13F filings cover US-listed holdings and arrive up to 45 days after quarter end, so positions may have changed since.
Stakes of 5% or more
No 13D or 13G filing on XENE in the last two years from the filings we read (13G only for companies we track; the sweep began Sep 2026).
A 13D means the holder crossed 5% with intent beyond passive ownership and had to state a purpose; a 13G is the passive version. Every new 13D on tracked companies.